Media headlines about Bio-Techne (NASDAQ:TECH) have trended somewhat positive on Wednesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bio-Techne earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.3520280551359 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Bio-Techne’s (TECH) “Buy” Rating Reaffirmed at Leerink Swann (americanbankingnews.com)
- Single Cell Analysis Market By Product Consumable, Instruments Opportunity Analysis 2025 (reports.pr-inside.com)
- Global Stem Cell Assay Market to reach USD 1358.1 Million by 2021 |Market data forecast (reports.pr-inside.com)
- TECH Crosses Above Average Analyst Target (nasdaq.com)
- Bio-Techne Corp (TECH) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
Several equities research analysts have recently weighed in on the company. Leerink Swann reissued a “buy” rating on shares of Bio-Techne in a report on Tuesday. BidaskClub downgraded Bio-Techne from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised Bio-Techne from a “hold” rating to a “buy” rating and set a $143.00 price target for the company in a report on Saturday, November 4th. Deutsche Bank set a $145.00 price target on Bio-Techne and gave the stock a “buy” rating in a report on Tuesday, October 31st. Finally, Citigroup reaffirmed a “buy” rating and set a $115.00 price target (down from $125.00) on shares of Bio-Techne in a report on Tuesday, October 24th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Bio-Techne currently has an average rating of “Buy” and an average price target of $134.33.
Bio-Techne (NASDAQ TECH) traded up $0.25 during trading on Wednesday, reaching $128.72. The company’s stock had a trading volume of 146,825 shares, compared to its average volume of 166,609. Bio-Techne has a 12 month low of $95.68 and a 12 month high of $136.39. The company has a current ratio of 2.87, a quick ratio of 2.25 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $4,862.97, a P/E ratio of 37.41, a P/E/G ratio of 3.24 and a beta of 0.75.
Bio-Techne (NASDAQ:TECH) last released its earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. Bio-Techne had a return on equity of 14.11% and a net margin of 12.54%. The company had revenue of $144.61 million during the quarter, compared to the consensus estimate of $142.37 million. During the same quarter last year, the company earned $0.84 earnings per share. Bio-Techne’s quarterly revenue was up 10.7% compared to the same quarter last year. equities analysts anticipate that Bio-Techne will post 3.76 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 24th. Shareholders of record on Friday, November 10th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend was Thursday, November 9th. Bio-Techne’s dividend payout ratio (DPR) is currently 66.32%.
In other Bio-Techne news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $130.18, for a total value of $650,900.00. Following the completion of the sale, the director now owns 12,712 shares of the company’s stock, valued at $1,654,848.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 5,200 shares of company stock valued at $675,190. 3.40% of the stock is owned by corporate insiders.
Bio-Techne Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.